From: Innate immune responses in hepatitis B virus (HBV) infection
Experimental model | Mechanism | HBV protein involved | Functional outcome | Reference |
---|---|---|---|---|
Human hepatocyte cell line | Inhibition of IRF3 | HBV polymerase | Inhibition of IFN-β induction | [52] |
Hepatoma cell lines, liver tumor samples | MAVS degradation | HBx | Prevention of IFN-β induction | [55] |
Hepatoma cell lines | Blocking DDX3 DEAD box RNA helicase | HBV polymerase | Inhibition of IFN-β promoter in response to RIG-I/MDA5 and TLR3 | [51] |
Hepatoma cell lines, HBx transgenic mouse | HBx binding to IPS-1 | HBx | Inhibition of IFN-β induction | [54] |
Hepatoma cell lines | Binding and inactivation of mitochondrial membrane protein virus-induced signalling adaptor (VISA) | HBx | Inhibition of virus-triggered IRF3 activation and IFN-β induction | [53] |
HBV transgenic mice and hepatoma cell lines |  | HBsAg, HBeAg, or HBV virions | Suppression of TLR 1-9 induced activation of IRF3, NF-κB, ERK1/2 and IFN-β production | [58] |
VSV infection of hepatoma cell lines and monocyte-derived dendritic cells from patients with HBV infection |  |  | Reduced RIG-I expression and IFN-β production | [50] |